Navigation Links
NeurogesX Receives European Commission Approval for Qutenza(TM)
Date:5/21/2009

Approved for peripheral neuropathic pain in non-diabetic adults

SAN MATEO, Calif., May 21 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that the European Commission has formally granted marketing authorization of Qutenza(TM) 179 mg cutaneous patch (formerly NGX-4010) for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain. Qutenza can only be obtained with a prescription. The centralized marketing authorization allows Qutenza to be marketed in all 27 countries of the European Union.

The approval of Qutenza follows a positive opinion recommending approval from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) on March 19, 2009. Qutenza, a cutaneous (dermal) patch, is designed to locally deliver a high-concentration (8%) of the active substance capsaicin and to provide sustained relief from peripheral neuropathic pain. Following application to the painful areas on the skin, Qutenza is allowed to remain in place for 30 minutes for the feet (e.g., HIV-associated neuropathy) and 60 minutes for other locations (e.g., postherpetic neuralgia). Qutenza is not indicated for adults who have diabetes as there is only limited experience with Qutenza in patients with Painful Diabetic Neuropathy (PDN), and repeated treatments with Qutenza in patients with PDN have not been studied.

NeurogesX anticipates that Qutenza will be marketed in the European Union through a commercial partner.

Anthony DiTonno, President and CEO, commented, "The European approval of Qutenza represents a major milestone for NeurogesX. It marks the culmination of years of developm
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... recommend Corvalen(R) D-Ribose to boost cellular energy, NEW YORK, ... you,could sleep all year and not catch up? That,s how ... there was a good reason to be,exhausted -- five boys ... fix., Then came a sixth son, and she began ...
... System Combines Clinical Benefits of Dual Wavelengths Through ... Time While Providing a Uniform, Safe and Effective ... Treatment - New Offering Signals Company,s Expansion into International Laser ... Lipolysis Market, WESTFORD, Mass., April 28 Cynosure, ...
... Calif., April 28 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: ... its Phase 2 testing results of Rh-Apo2L and,expects to ... announced that the target cancers for the drug have ... targets,that the Company has chosen are ailments which Rh-Apo2L ...
Cached Biology Technology:D-Ribose Helps Energy-Starved Hearts 2Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 2Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 3Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 4Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 5Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing 2
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
(Date:7/11/2014)... near the City of Entiat on Tuesday, July 8, ... quickly grew to over 1,000 acres by evening. Three ... under investigation by the Washington Department of Natural Resources. ... resources in developing fire control strategies and tactics. Other ... Department of Natural Resources, (WA DNR), Bureau of Land ...
(Date:7/11/2014)... is creating a new professorship in tissue engineering ... for Molecular Engineering and the Marine Biological Laboratory, ... Millicent and Eugene Bell Foundation., The Eugene Bell ... Institute for Molecular Engineering. That endowed chair holder ... MBL,s Eugene Bell Center for Regenerative Biology and ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New professorship in tissue engineering links molecular engineering, marine biology 2
... the atmosphere through summer thunderstorm clouds, according to a ... Letters . How much the warming effect of these ... not yet clear. To find out, researchers need to ... Pollution strengthens thunderstorm clouds, causing their anvil-shaped tops ...
... rate at which the rabies virus evolves in bats may ... to researchers at the University of Georgia, the U.S. Centers ... Belgium. Their study, published May 17 in the journal ... the most accurate predictor of the viral rate of evolution. ...
... physicists and University of Miami biologists addresses an ... do living cells figure out when and where ... Dimitrios Vavylonis and Associate Professor Fulvia Verde discovered ... a ballet of proteins that change its polarity. ...
Cached Biology News:Pollution teams with thunderclouds to warm atmosphere 2Pollution teams with thunderclouds to warm atmosphere 3Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 2Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 3A cell's first steps: Building a model to explain how cells grow 2
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: